Literature DB >> 17913486

Dispensing of antibiotics, antitussives and mucolytics to asthma patients: a pharmacy-based observational survey.

Laurent Laforest1, Eric Van Ganse, Gilles Devouassoux, A El Hasnaoui, Liesl M Osman, Gisele Bauguil, Genevieve Chamba.   

Abstract

BACKGROUND: Antibiotics, antitussives and mucolytics are commonly used in asthma, despite limited evidence for their effectiveness. The correlates of use for these medication classes in asthma were identified.
METHODS: Asthma patients aged 18-50 who were regular customers of pharmacies were included in an observational study. Patients completed a questionnaire, which was complemented by computerised pharmacy records of previously dispensed medications. Users of each drug class were compared to non-users in terms of demographics, asthma characteristics and management.
RESULTS: Among 886 patients (mean age: 37; 55% females), 63.2%, 55.8% and 27.2%, respectively, were users of antibiotics, mucolytics and antitussives during the previous 12 months. In multivariate analysis, dispensing of >2 units of oral corticosteroids was the major correlate of receiving antibiotics (OR=5.47; 95% CI=[3.00-9.97]), mucolytics (OR=3.93; 95% CI=[2.38-6.50]) and antitussives (OR=1.86; 95% CI=[1.18-2.94]). Compared to well-controlled patients, the probability of receiving antibiotics was significantly higher for poorly controlled patients (OR=2.01; 95% CI=[1.28-3.15]).
CONCLUSIONS: Our results suggest that these drugs are mainly used during asthma exacerbations. A better understanding of the use of co-medication in asthma is required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17913486     DOI: 10.1016/j.rmed.2007.08.004

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  1 in total

1.  Prescribed therapy for asthma: therapeutic ratios and outcomes.

Authors:  Laurent Laforest; Idlir Licaj; Gilles Devouassoux; Irene Eriksson; Pascal Caillet; Gérard Chatte; Manon Belhassen; Eric Van Ganse
Journal:  BMC Fam Pract       Date:  2015-04-14       Impact factor: 2.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.